---
layout: default
title: Vigabatrin
description: "Vigabatrin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 190
evidence_level: L5
indication_count: 0
---

# Vigabatrin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>0</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Vigabatrinï¼šæŠ—ç™²ç™‡è¼”åŠ©ç™‚æ³•

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Vigabatrin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Vigabatrin æ˜¯ä¸€ç¨®ç”¨æ–¼æŠ—ç™²ç™‡è¼”åŠ©ç™‚æ³•çš„è—¥ç‰©ã€‚
TxGNN æ¨¡å‹**æœªé æ¸¬**å‡ºä»»ä½•æ–°çš„é©æ‡‰ç—‡ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æŠ—ç™²ç™‡ä¹‹è¼”åŠ©ç™‚æ³• |
| é æ¸¬æ–°é©æ‡‰ç—‡ |  |
| TxGNN é æ¸¬åˆ†æ•¸ | N/A |
| è­‰æ“šç­‰ç´š | N/A |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 6 å¼µï¼ˆ2 å¼µæœ‰æ•ˆï¼‰ |
| å»ºè­°æ±ºç­– | ç„¡è€è—¥æ–°ç”¨å€™é¸ |

## ç‚ºä»€éº¼æ²’æœ‰é æ¸¬æ–°é©æ‡‰ç—‡ï¼Ÿ

Vigabatrin æ˜¯ä¸€ç¨®é¸æ“‡æ€§ GABA è½‰èƒºé…¶ï¼ˆGABA-Tï¼‰ä¸å¯é€†æŠ‘åˆ¶åŠ‘ï¼Œé€éæŠ‘åˆ¶ 4-aminobutyrate aminotransferase å¢åŠ è…¦å…§ GABA æ¿ƒåº¦ã€‚å…¶ä½œç”¨æ©Ÿè½‰é«˜åº¦å°ˆä¸€ï¼Œä¸»è¦é‡å°ç™²ç™‡ç›¸é—œçš„ç¥ç¶“å‚³å°ç•°å¸¸ï¼Œå› æ­¤åœ¨ TxGNN çŸ¥è­˜åœ–è­œåˆ†æä¸­æœªç™¼ç¾èˆ‡å…¶ä»–ç–¾ç—…çš„é¡¯è‘—é—œè¯ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç„¡ç›¸é—œæ–°é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ã€‚

## æ–‡ç»è­‰æ“š

ç„¡ç›¸é—œæ–°é©æ‡‰ç—‡çš„æ–‡ç»è­‰æ“šã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ | ç‹€æ…‹ |
|---------|------|------|-----------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028723è™Ÿ | å¿…æŠ—ç™²å£æœæº¶æ¶²ç”¨ç²‰åŠ‘500æ¯«å…‹ | å£æœæº¶æ¶²ç”¨ç²‰åŠ‘ | æŠ—ç™²ç™‡ä¹‹è¼”åŠ©ç™‚æ³• | æœ‰æ•ˆ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬021847è™Ÿ | èµ¦ç™²æ˜“è†œè¡£éŒ 500å…¬çµ² | è†œè¡£éŒ  | æŠ—ç™²ç™‡ä¹‹è¼”åŠ©ç™‚æ³• | æœ‰æ•ˆ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬021691è™Ÿ | è†œè¡£éŒ 500å…¬çµ² | è†œè¡£éŒ  | æŠ—ç™²ç™‡ä¹‹è¼”åŠ©ç™‚æ³• | å·²è¨»éŠ· |
| è¡›ç½²è—¥è¼¸å­—ç¬¬020477è™Ÿ | èµ¦ç™²æ˜“éŒ 500å…¬çµ² | å¤–ç”¨éŒ åŠ‘ | æŠ—ç™²ç™‡ä¹‹è¼”åŠ©ç™‚æ³• | å·²è¨»éŠ· |

## å®‰å…¨æ€§è€ƒé‡

### é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆMajorï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡åº¦ |
|-------------|--------|
| Hydrocortisone | Major |
| Triamcinolone | Major |
| Dexamethasone | Major |
| Betamethasone | Major |
| Budesonide | Major |
| Prednisone | Major |
| Prednisolone | Major |
| Methylprednisolone | Major |
| Deflazacort | Major |
| Deferoxamine | Major |
| Chloroquine | Major |
| Hydroxychloroquine | Major |
| Quinine | Major |
| Tamoxifen | Major |

### ä¸­åº¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆModerateï¼‰

èˆ‡å¤šç¨®é®éœåŠ‘ã€æŠ—çµ„ç¹”èƒºè—¥ç‰©åŠé¡é´‰ç‰‡è—¥ç‰©æœ‰ä¸­åº¦äº¤äº’ä½œç”¨ï¼Œå¯èƒ½å¢åŠ ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶ä½œç”¨ã€‚å¸¸è¦‹åŒ…æ‹¬ï¼šMorphineã€Codeineã€Cetirizineã€Diphenhydramineã€Ethanol ç­‰ã€‚

### ä½œç”¨æ¨™é¶

- Vesicular inhibitory amino acid transporter (SLC32A1)
- 4-aminobutyrate aminotransferase (ABAT)

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities r...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šåš´é‡ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶é¢¨éšª
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Depressive Disorder** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šAntiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indicat...

**Neurotoxicity Syndromes** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šVigabatrin has produced pathological changes in the brains of rats and long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, le...

**Peripheral Nervous System Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šVigabatrin causes symptoms of peripheral neuropathy in adults...

**Blindness** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šç„¡è€è—¥æ–°ç”¨å€™é¸**

**ç†ç”±ï¼š**
Vigabatrin çš„ä½œç”¨æ©Ÿè½‰é«˜åº¦å°ˆä¸€æ–¼ GABA èƒ½ç¥ç¶“å‚³å°ï¼ŒTxGNN æ¨¡å‹æœªç™¼ç¾å…·æœ‰è¶³å¤ è­‰æ“šæ”¯æŒçš„æ–°é©æ‡‰ç—‡å€™é¸ã€‚

**æ³¨æ„äº‹é …ï¼š**
- Vigabatrin å¯èƒ½å°è‡´ä¸å¯é€†çš„è¦–é‡ç¼ºæï¼Œéœ€å®šæœŸç›£æ¸¬è¦–åŠ›
- èˆ‡çš®è³ªé¡å›ºé†‡ä½µç”¨éœ€ç‰¹åˆ¥æ³¨æ„äº¤äº’ä½œç”¨

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol]({{ "/drugs/polyethylene_glycol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nepafenac]({{ "/drugs/nepafenac/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Timepidium]({{ "/drugs/timepidium/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Urea]({{ "/drugs/urea/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Vigabatrinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/vigabatrin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_vigabatrin,
  title = {Vigabatrinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vigabatrin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
